Methoxetamine (MXE) - A Phenomenological Study of Experiences Induced by a "Legal High" from the Internet

Journal of Psychoactive Drugs

Volumn 45, Issue 3, 2013, Pages 276-286

  Kjellgren, Anette ^a   Jonsson, Kristoffer ^a  

^a KARLSTAD UNIVERSITY   (Sweden)

Author keywords

altered states of consciousness; hallucinogen; Internet drug; legal high; methoxetamine; MXE; psychedelic

Indexed keywords

KETAMINE; LYSERGIC ACID; METHOXETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PSILOCYBINE; UNCLASSIFIED DRUG;

ADDICTION; ANTICIPATION; ANXIETY; APHASIA; ARTICLE; CONFUSION; CONSCIOUSNESS DISORDER; DEPERSONALIZATION; EXPERIENCE; HUMAN; LEARNING; MOTIVATION; NAUSEA AND VOMITING; NERVOUSNESS; PARANOIA; PHENOMENOLOGY; QUALITATIVE RESEARCH; RESTLESSNESS; SENSORY DYSFUNCTION; SIDE EFFECT; TRANSCENDENTAL MEDITATION;

COGNITION; CYCLOHEXANONES; CYCLOHEXYLAMINES; FEMALE; HALLUCINOGENS; HUMANS; INTERNET; MALE; MOTIVATION; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 84881647287     PISSN: 02791072     EISSN: 21599777     Source Type: Journal    
DOI: 10.1080/02791072.2013.803647     Document Type: Article

References (46)

1. Aan Het Root, M., Charney, D.S. and Mathew, S.J. 2008. Intravenous ketamine for treatment resistant major depressive disorder. Primary Psychiatry, 15 (4): 39 - 47.
2. Babu, K., Boyer, E.W., Hernon, C. and Brush, E. 2005. Emerging drugs of abuse. Pediatric Emergency Medicine, 6 (2): 81 - 84.
3. Babu, K.M., McCurdy, C.R. and Boyer, E.W. 2008. Opioid receptors and legal highs: Salvia divinorum and Kratom. Clinical Toxicology, 46 (2): 146 - 152.
4. Benthuysen, J.L., Hance, A.J., Quam, D.D. and Winters, W.D. 1989. Comparison of isomers of Ketamine on catalepsy in the rat and electrical activity of the brain and behavior in the cat. Neuropharmacology, 28 (10): 1003 - 1009.
5. Berman, R.M., Cappiello, A., Anand, A., Oren, D.A., Heninger, G.R., Charney, D.S. and Krystal, J.H. 2000. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry, 47 (4): 351 - 354.
6. Bonta, I.L. 2004. Schizophrenics, dissociative anesthesia and near-death experiences: Three events meeting at the NMDA receptor. Medical Hypotheses, 62 (1): 23 - 28.
7. Corazza, O. and Schifano, F. 2010. Near-death states reported in a sample of 50 misusers. Substance Use and Misuse, 45 (6): 916 - 924.
8. Corazza, O., Schifano, F., Simonato, P., Fergus, S., Assi, S., Stair, J., Corkery, J., Trincas, G. and Scherbaum, N. 2012. Phenomenon of new drugs on the Internet: The case of ketamine derivative methoxetamine. Human Psychopharmacology: Clinical and Experimental, 27 (2): 145 - 149.
9. Erickson, F. 1989. The meaning of validity in qualitative research, M.C. Wittrock (Ed.) Handbook of Research on Teaching. New York: Macmillan.
10. European Monitoring Centre for Drugs and Drug Addiction-Europol (EMCDDA). 2011. 2011 Annual Report on the State of the Drug Problem in Europe. Available at:. Accessed April 5, 2012 http://www.emcdda.europa.eu/publications/annual-report/2011 (http://www.emcdda.europa.eu/publications/annual-report/2011)
11. Gibbons, S. 2012. Legal highs: Novel and emerging psychoactive drugs: A chemical overview for the toxicologist. Clinical Toxicology, 50 (1): 15 - 24.
12. Griffiths, R.R., Richards, W.A., McCann, U. and Jesse, E. 2006. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and significance. Psychopharmacology, 187 (3): 268 - 283.
13. Groth-Marnat, G. and Summers, G. 1998. Altered beliefs, attitudes, and behaviours following near-death experiences. Journal of Humanistic Psychology, 38 (3): 110 - 125.
14. Hayes, C.H., Strosahl, K.D. and Wilson, G.W. 2012. Acceptance and Commitment Therapy: The Process and Practice of Mindful Change, New York: The Guilford Press.
15. Hayes, S.C., Luoma, J.B., Bond, F.W., Masuda, A. and Lillis, J. 2005. Acceptance and commitment therapy: Model, processes and outcomes. Behavioral Research and Therapy, 44 (1): 1 - 25.
16. Hays, P.A.; Casale, J.F. & Berrier, A.L. The characterization of 2-(3-Methoxyphenyl)-2- (ethylamino)cyclohexanone (methoxetamine). Microgram Journal 9 (1): 3-17. Available at: 17.pdf. Accessed November 27, 2012 http://www.justice.gov/dea/pr/microgram-journals/2012/mj9-1_3- (http://www.justice.gov/dea/pr/microgram-journals/2012/mj9-1_3-)
17. Hofer, K.E., Grager, B., Muller, D.M., Rauber-Luthy, C., Kupferschmidt, H., Rentsch, K.M. and Ceschi, A. 2012. Ketamine-like effects after recreational use of methoxetamine. Annals of Emergency Medicine, 60 (1): 97 - 99.
18. Jansen, K.L.R. 1989. Near-death experiences and the NMDA receptor. British Medical Journal, 298 (6689): 1708
19. Jansen, K.L.R. 2001. Ketamine: Dreams and Realities, Sarasota, FL: MAPS.
20. Karlsson, G. 1995. Psychological Qualitative Research from a Phenomenological Perspective, Stockholm: Almqvist & Wiksell International.
21. Khorramzadeh, E. and Lofty, A.O. 1973. The use of ketamine in psychiatry. Psychosomatics: Journal of Consultation Liaison Psychiatry, 14 (6): 344 - 346.
22. Kjellgren, A. and Soussan, C. 2011. Heaven and hell - A phenomenological study of recreational use of 4-HO-MET in Sweden. Journal of Psychoactive Drugs, 43 (3): 211 - 219.
23. Krupitsky, E. and Kolp, E. 2007. " Ketamine psychedelic psychotherapy ". In Psychedelic Medicine: New Evidence for Hallucinogenic Substances as Treatments, Edited by: Winkelman, M. J. and Roberts, T. B. Westport, CT: Greenwood Publishing Group, Inc.
24. MacLean, K.A., Johnson, M.W. and Griffiths, R.R. 2011. Mystical experiences occasion by the hallucinogen psilocybin lead to increase in the personality domain of openess. Journal of Psychopharmacology, 25 (11): 1453 - 1461.
25. Markou, A., Kosten, T.R. and Koob, G.F. 1998. Neurobiological similarities in depression and drug dependence: A self-medication hypothesis. Neuropsychopharmacology, 18: 135 - 174.
26. Martin, L.L. and Kleiber, D.A. 2005. Letting go of the negative: Psychological growth from a close brush with death. Traumatology, 11 (4): 221 - 232.
27. Metzner, R. 1998. Hallucinogenic drugs and plants in psychotherapy and shamanism. Journal of Psychoactive Drugs, 30 (4): 331 - 341.
28. Moore, N.N. and Bostwick, J.M. 1999. Ketamine dependence in anesthesia providers. Psychosomatics: Journal of Consultation Liaison Psychiatry, 40 (4): 356 - 359.
29. Morris, H. 2011. Interview with a ketamine chemist: Or to be more precise, an arylcyclohexylamine chemist. Vice Magazine. Available at:. Accessed October 11, 2011 www.vice.com/read/interview-with-ketaminechemist-704-v18n2 (http://www.vice.com/read/interview-with-ketaminechemist-704-v18n2)
30. Patton, M.Q. 2002. Qualitative Evaluation and Research Method, Thousand Oaks, CA: Sage Publications Inc.
31. Rosenbaum, C.D., Carrero, S.P. and Babu, K.M. 2012. Here today, gone tomorrow... and back again? A review of herbal marijuana alternatives (K2, spice), synthetic cathinones (bath salts), kratom, salvia divinorum, methoxetamine, and piperazines. Journal of Medical Toxicology, 8 (1): 15 - 32.
32. Ross, S. 2008. Ketamine and addiction. Primary Psychiatry, 15 (9): 61 - 69.
33. Schmidt, M.M., Sharma, A., Schifano, F. and Feinman, C. 2011. Legal highs on the net - Evaluation of UK-based websites, products and product information. Forensic Science International, 206 (1-3): 92 - 97.
34. Shields, J.E., Dargan, P.I., Wood, D.M., Puchnarewicz, M., Davies, S. and Waring, W.S. 2012. Methoxetamine associated reversible cerebellar toxicity: Three cases with analytical confirmation. Clinical Toxicology, 50 (5): 438 - 440.
35. Strauss, A. and Corbin, J. 1990. Basics of Qualitative Research: Grounded Theory Procedures and Techniques, Newbury Park, CA: Sage Publications, Inc.
36. Thangathurai, D. and Mogos, M. 2011. Ketamine alleviates fear, depression, and suicidal ideation in terminally ill patients. Journal of Palliative Medicine, 14 (4): 389
37. UK Advisory Council on the Misuse of Drugs. 2011. Consideration of the novel psychoactive substances ("legal highs").Available at: acmdnps2011?view=Binary. Accessed April 15, 2012 http://www.homeoffice.gov.uk/publications/agencies-public-bodies/acmd1/ (http://www.homeoffice.gov.uk/publications/agencies-public-bodies/acmd1/)
38. Vardaku, I., Pistos, C. and Spiliopoulou, C. 2010. Drugs for youth via Internet and the example of mephedrone. Toxicology Letters, 201 (3): 191 - 195.
39. Vollenweider, F.X., Vontobel, P., Oye, I., Hell, D. and Leenders, K.L. 2000. Effects of (S) ketamine on striatal dopamine: A raclopride PET study of a model psychosis in humans. Journal of Psychiatric Research, 34 (1): 35 - 43.
40. Ward, J., Rhyee, S., Plansky, J. and Boyer, E. 2011. Methoxetamine: A novel ketamine analog and growing health-care concern. Clinical Toxicology, 49 (9): 874 - 875.
41. Winstock, A.R., Mitcheson, L., Gillatt, D.A. and Cottrell, A.M. 2012. The prevalence and natural history of urinary symptoms among recreational ketamine users. BJU International 110 (11): 1762-1766, Mar 14 doi: 10.1111/j.1464-410X.2012.11028
42. Wohlfarth, A. and Weinmann, W. 2010. Bioanalysis of new designer drugs. Bioanalysis, 2 (5): 965 - 979.
43. Wolff, K. and Winstock, A.R. 2006. Ketamine: From medicine to misuse. CNS Drugs, 20 (3): 199 - 218.
44. Wood, D.M., Davies, S., Puchnarewicz, M., Johnston, A. and Dargan, P.I. 2012. Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine. European Journal of Clinical Pharmacology, 68 (5): 853 - 856.
45. Zarate, C.A., Singh, J.B., Carlson, P.J., Brutsche, N.E., Ameli, R. and Luckenbaugh, D.A. 2006. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry, 63 (8): 56 - 864.
46. Zawilska, J.B. 2011. "Legal highs" - new players in the old drama. Current Drug Abuse Reviews, 4 (2): 122 - 130.